Treatment at High-volume Hospitals Improves Survival in Women with Ovarian Cancer (10/19/2009)
Researchers from Finland have reported that low hospital volume is associated with residual tumor in women with ovarian cancer. The details of this study appeared in the November, 2009 issue of Gynecologic Oncology.

Doxil® and Paraplatin® Superior to Taxol® and Paraplatin for Relapsed Ovarian Cancer (10/1/2009)
Researchers affiliated with the Gynecologic Cancer Intergroup (CCIG) trial CALYPSO have reported that Doxil®, also marketed as Caelyx® and Myocet® (pegylated liposomal doxorubicin) and Paraplatin® (carboplatin) was more effective and better tolerated than Taxol® (paclitaxel) and Paraplatin for partially platinum-sensitive ovarian cancer (patients who relapse between six and 12 months). The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.

New Monoclonal Antibody, Farletuzumab, May Have Activity in Relapsed Ovarian Cancer (10/1/2009)
Researchers involved in a multicenter Phase II clinical trial have reported that the addition of farletuzumab (MORab-003) to a taxane and a platinum compound increases the response rate in women with platinum-sensitive relapse compared with historical controls. The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.

High Time Costs for Informal Care Givers of Cancer Patients (9/10/2009)
Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.

Women Report Symptoms to Primary Care Physicians Prior to Diagnosis of Ovarian Cancer (9/1/2009)
Researchers from the UK have reported that women with ovarian cancer usually report symptoms to primary care physicians before the diagnosis. These researchers suggest that these symptoms should be included in guidelines for diagnostic testing. The details of this study appeared online in the British Medical Journal on August 25, 2009.